Evaluation of Diagnosis Season and in Situ Hybridization EBER Results in Hodgkin Lymphoma: A Single Center Retrospective Study
Makaleler > Tam Makale · 2025
Yazarlar: Damla Çağla PATIR, Özlem LİMONCU, Derya DEMİR, Nazan ÖZSAN, Mine HEKİMGİL, Ajda GÜNEŞ, Nur SOYER, Fahri ŞAHİN, Filiz VURAL, Güray SAYDAM, Mahmut TÖBÜ
Turkiye Klinikleri Journal of Medical Sciences, Uluslararası, Scopus, 2025, cilt 45, ss 158-165
DOI: 10.5336/medsci.2024-107137
Özet
Objective: Hodgkin lymphoma (HL) is a hematological malignancy with a generally favorable prognosis, yet its pathogenesis remains unclear, and unknown risk factors affecting incidence and mortality are still being explored. This study aimed to assess the influence of diagnosis season and the presence of in situ hybridization (ISH) Epstein-Barr encoded RNA (EBER) on HL survival. Material and Methods: We evaluated 232 HL patients treated at Ege University Faculty of Medicine Hematology Clinic from January 1, 1994, to December 31, 2023. Results: Among the 232 patients (41.4% female and 58.6% male), the mean age at diagnosis was 38.42 years (SD: 15.99), with a median age of 35. The most common subtype was nodular sclerosing (47%), followed by mixed cellularity (29.3%) and nodular lymphocyte predominant (NLP) (9.9%). EBER was detected in 45.7% of patients, while 54.3% were EBER negative. The highest diagnosis rate occurred in winter (30.6%), and the lowest in spring (19.8%). EBER presence did not vary by season, and no significant difference in overall survival times was found between EBER positive and negative patients (p=0.427). Conclusion: Our findings indicate that EBER positivity does not significantly impact the prognosis of HL, with no seasonal variability in EBER rates. The lack of significant survival differences suggests that EBER has limited relevance in HL management. These insights contribute to the understanding of HL's clinical practice and pathogenesis, highlighting areas for future research.